Innovative WEF-style forums will gather experts from the corporate, neuroscience, and clinical fields to discuss breakthroughs in neurodegeneration research. These sessions aim to advance our understanding and treatment of Alzheimer’s and Parkinson’s diseases by exchanging new insights and addressing current challenges. Each forum features brief introductions by participants, followed by an audience Q&A, with media coverage to share progress in the field.
Forum Date & Title
Co-Moderators
Discussants
FIRESIDE DEBATE: MOONSHOTS AND MILESTONES: IS THE FUTURE OF NEURODEGENERATION DRUG DISCOVERY IN STARTUPS, BIG PHARMA, OR ACADEMIA?
- Henrietta Nielsen
- Phillip Scheltens
- TBA
BIOMARKERS TO BENEFIT: ACCELERATING TRANSLATION OF MULTI-MODAL BIOMARKERS INTO DISEASE-MODIFYING THERAPIES
- Melissa Murray
- Oskar Hansson
- TBA
REWIRING COGNITION: TARGETING CHOLINERGIC, SYNAPTIC, AND NETWORK-BASED MECHANISMS IN AD, PD, AND LBD
- Manfred Windisch
- Jeffrey Cummings
- TBA
BEYOND AMYLOID AND TAU: EMERGING TARGETS AND MULTI-PATHWAY APPROACHES IN NEURODEGENERATION AND NEUROINFLAMMATION – PROMISE AND PITFALLS
- David Holtzman
- Cynthia Lemere
- TBA
BEYOND AMYLOID AND TAU: EMERGING TARGETS AND MULTI-PATHWAY APPROACHES IN NEURODEGENERATION AND NEUROINFLAMMATION – PROMISE AND PITFALLS
- Randall Bateman
- TBA
- TBA
IMMUNOTHERAPY 2.0: REDEFINING MICROGLIAL, TREM2, AND ADAPTIVE IMMUNE ENGAGEMENT IN AD AND PD
- TBA
- TBA
TARGETS TO THERAPIES: TRANSLATIONAL R&D FOR Α-SYNUCLEIN, LRRK2, AND GBA PATHOLOGIES IN PD, LBD, AND MSA
- Jamie Eberling
- Ken Marek
- TBA